Skip to search formSkip to main contentSkip to account menu

Epoprostenol

Known as: PGI2, PGX, Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)- 
An oral prostacyclin and a metabolite of arachidonic acid with antihypertensive and platelet inhibitory properties. Epoprostenol binds to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Oxidative stress plays a pivotal role in the development of diabetes complications, both microvascular and cardiovascular. The… 
Highly Cited
2004
Highly Cited
2004
The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a… 
Highly Cited
2002
Highly Cited
2002
Background—Primary pulmonary hypertension (PPH) is a severe and progressive disease. Without treatment, the median survival is 2… 
Review
2002
Review
2002
The peroxisome proliferator-activated receptors (PPARs) are a group of three nuclear receptor isoforms, PPAR gamma, PPAR alpha… 
Highly Cited
2002
Highly Cited
2002
Review
2001
Review
2001
SUMMARY The gram-positive bacterium Listeria monocytogenes is the causative agent of listeriosis, a highly fatal opportunistic… 
Review
2000
Review
2000
Pulmonary hypertension is characterized by progressive elevation of pulmonary artery pressure and vascular resistance, often… 
Highly Cited
1996
Highly Cited
1996
BACKGROUND Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective… 
Highly Cited
1990
Highly Cited
1990
STUDY OBJECTIVE To determine the efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) in primary pulmonary… 
Highly Cited
1976
Highly Cited
1976
Microsomes prepared from rabbit or pig aortas transformed endoperoxides (PGG2 or PGH2) to an unstable substance (PGX) that…